Fosamax (Alendronate Sodium), a biphosphonate drug manufactured by pharmaceutical company Merck, is commonly used to treat osteoporosis in menopausal women. The drug has shown effective bone strengthening action for the first four years of drug intake. But new studies has shown that Fosamax may deliberately risk the individual to experience atypical, low-impact femur fracture, a phenomena already experienced by Fosamax users as they had claimed. Nevertheless, there are other treatments yo...